MediciNova (NASDAQ:MNOV) Upgraded at Zacks Research

Zacks Research upgraded shares of MediciNova (NASDAQ:MNOV) to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Several other analysts have also recently commented on the stock. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of MediciNova in a research note on Friday, January 30th. HC Wainwright started coverage on shares of MediciNova in a report on Monday. They set a “buy” rating and a $10.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of MediciNova in a research report on Monday, December 29th. Finally, Lucid Cap Mkts raised MediciNova to a “strong-buy” rating in a report on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, MediciNova currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

MediciNova Price Performance

MediciNova stock opened at $1.39 on Tuesday. The business has a 50 day simple moving average of $1.54 and a 200-day simple moving average of $1.42. MediciNova has a 12 month low of $1.13 and a 12 month high of $1.96. The stock has a market capitalization of $68.42 million, a PE ratio of -5.79 and a beta of 0.58.

MediciNova (NASDAQ:MNOV) last posted its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The firm had revenue of $0.15 million during the quarter. As a group, equities research analysts anticipate that MediciNova will post -0.24 EPS for the current year.

Hedge Funds Weigh In On MediciNova

A number of large investors have recently made changes to their positions in MNOV. Jane Street Group LLC acquired a new stake in shares of MediciNova in the 4th quarter worth approximately $214,000. Citadel Advisors LLC acquired a new position in MediciNova during the third quarter worth $92,000. Goldman Sachs Group Inc. purchased a new stake in MediciNova during the fourth quarter worth $35,000. StoneX Group Inc. purchased a new stake in MediciNova during the fourth quarter worth $25,000. Finally, State Street Corp grew its holdings in MediciNova by 10.9% in the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 19,100 shares during the last quarter. Hedge funds and other institutional investors own 9.90% of the company’s stock.

Trending Headlines about MediciNova

Here are the key news stories impacting MediciNova this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $10 price target, highlighting a bullish long‑term thesis that implies significant upside from current levels. HC Wainwright Initiates Coverage on MediciNova
• Positive Sentiment: HC Wainwright published multi-year EPS forecasts showing small expected losses in FY2026–FY2027 followed by projected profitability in FY2028–FY2030 (ramping to ~$3.02 EPS by FY2030). These modeled tailwinds support the Buy rating but depend on successful clinical / commercial execution. MarketBeat MNOV Coverage
• Positive Sentiment: Zacks Research upgraded MediciNova to “Hold,” a modestly positive signal that may reduce downside risk from prior weaker sentiment but is not a strong buy endorsement. Zacks Research
• Neutral Sentiment: Analysts still model near-term losses (consensus ~($0.24) FY2026); HC Wainwright’s FY2026 view is roughly in line (~($0.26)), underscoring that short‑term fundamentals remain weak while upside is tied to future catalysts.

About MediciNova

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.